We also identified a significantlyincreased number of CD14+HLA-DRneg/low MSC in the bloodof cancer patients as compared to healthy donors (P = .005),which tended to be lower after four or five weeks of VEGFR inhibition.Furthermore, we found that the frequencies of pMDCs, including MDC-1 and MDC-2,were significantly reduced in advanced cancer patients as compared to healthyindividuals. The gene discussed is ADAM22; the disease is cancer.